Global FDA footprint MagVenture holds FDA clearances for major depressive disorder and OCD indications across multiple MagPro stimulators, including Theta Burst options, signaling a broad opportunity to expand US clinic partnerships, hospital systems, and research centers leveraging TMS therapy.

Clinical depth With a diverse MagPro line and over 30 coils, MagVenture can tailor stimulation protocols for researchers and clinicians, enabling upsell of advanced coils, navigation options, and specialized programs to neuroscience labs, psychiatry clinics, and rehabilitation centers.

Expansion momentum Recent and ongoing product work such as SAINT Neuromodulation System development and Atlas Neuro Navigation launches indicate a pipeline of innovative offerings, creating cross-sell and renewal opportunities with existing customers seeking up-to-date technology.

Global reach, local Headquartered in Denmark with US FDA clearances and multinational product lines, MagVenture targets international hospitals, clinics, and academic institutions, presenting regions for channel partnerships, distributors, and contract sales roles.

Sustainability and reliability A focus on robust, research-grade magnetic stimulation systems suitable for long-term studies, combined with a history of regulatory clearances and scientific applications, supports value propositions around patient outcomes, cost-per-study, and long device lifecycles to win long-term procurement deals.